Table 1.

Definitions of the groups in the efficacy analysis

	Phase before A	MTX dosage at phase A (per week)	Phase after A	Number of trios
(A) Phase trio
Group T1	8 mg or less	Over 8 mg	Over 8 mg	262
Group T2	8 mg or less	Over 8 mg	8 mg or less	70
Group T3	8 mg or less	Over 8 mg	Over 8 mg (same value as phase A)	123
Group T4	8 mg	8 mg	8 mg	55

	Phase before A	MTX dosage at phase A (per week)	Number of pairs
(B) Phase pair
Group P1	8 mg or less	Over 8 mg	690
Group P2	8 mg	8 mg	2,125
Group P3	Over 8 mg	Over 8 mg	2,545

There are 6-month intervals between consecutive phases